These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

557 related articles for article (PubMed ID: 20437866)

  • 21. Relationship of established risk factors with breast cancer subtypes.
    McCarthy AM; Friebel-Klingner T; Ehsan S; He W; Welch M; Chen J; Kontos D; Domchek SM; Conant EF; Semine A; Hughes K; Bardia A; Lehman C; Armstrong K
    Cancer Med; 2021 Sep; 10(18):6456-6467. PubMed ID: 34464510
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Local-regional control according to surrogate markers of breast cancer subtypes and response to neoadjuvant chemotherapy in breast cancer patients undergoing breast conserving therapy.
    Caudle AS; Yu TK; Tucker SL; Bedrosian I; Litton JK; Gonzalez-Angulo AM; Hoffman K; Meric-Bernstam F; Hunt KK; Buchholz TA; Mittendorf EA
    Breast Cancer Res; 2012 May; 14(3):R83. PubMed ID: 22621334
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Risk and prognostic factors of breast cancer with liver metastases.
    Ji L; Cheng L; Zhu X; Gao Y; Fan L; Wang Z
    BMC Cancer; 2021 Mar; 21(1):238. PubMed ID: 33676449
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prognostic value of breast cancer subtypes, Ki-67 proliferation index, age, and pathologic tumor characteristics on breast cancer survival in Caucasian women.
    Ferguson NL; Bell J; Heidel R; Lee S; Vanmeter S; Duncan L; Munsey B; Panella T; Orucevic A
    Breast J; 2013; 19(1):22-30. PubMed ID: 23240985
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Distinct ER and PR expression patterns significantly affect the clinical outcomes of early HER2-positive breast cancer: A real-world analysis of 871 patients treated with neoadjuvant therapy.
    Chen H; Gui X; Zhou Z; Su F; Gong C; Li S; Wu W; Rao N; Liu Q; Yao H
    Breast; 2024 Jun; 75():103733. PubMed ID: 38615482
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Estrogen/progesterone receptor negativity and HER2 positivity predict locoregional recurrence in patients with T1a,bN0 breast cancer.
    Albert JM; Gonzalez-Angulo AM; Guray M; Sahin A; Strom EA; Tereffe W; Woodward WA; Tucker SL; Hunt KK; Hortobagyi GN; Buchholz TA
    Int J Radiat Oncol Biol Phys; 2010 Aug; 77(5):1296-302. PubMed ID: 20472353
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Age-specific incidence of breast cancer subtypes: understanding the black-white crossover.
    Clarke CA; Keegan TH; Yang J; Press DJ; Kurian AW; Patel AH; Lacey JV
    J Natl Cancer Inst; 2012 Jul; 104(14):1094-101. PubMed ID: 22773826
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The association between biological subtype and locoregional recurrence in newly diagnosed breast cancer.
    Gabos Z; Thoms J; Ghosh S; Hanson J; Deschênes J; Sabri S; Abdulkarim B
    Breast Cancer Res Treat; 2010 Nov; 124(1):187-94. PubMed ID: 20814819
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The Prognosis and Predictive Value of Estrogen Negative/Progesterone Positive (ER-/PR+) Phenotype: Experience of 1159 Primary Breast Cancer from a Single Institute.
    Gamrani S; Boukansa S; Benbrahim Z; Mellas N; Fdili Alaoui F; Melhouf MA; Bouchikhi C; Banani A; Boubbou M; Bouhafa T; El Fatemi H
    Breast J; 2022; 2022():9238804. PubMed ID: 35711896
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Clinicopathological differences and survival benefit in ER+/PR+/HER2+ vs ER+/PR-/HER2+ breast cancer subtypes.
    Ding W; Ye D; Chen H; Lin Y; Li Z; Tu C
    Breast Cancer; 2024 Mar; 31(2):295-304. PubMed ID: 38231460
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Estrogen receptor-positive, progesterone receptor-negative breast cancer: association with growth factor receptor expression and tamoxifen resistance.
    Arpino G; Weiss H; Lee AV; Schiff R; De Placido S; Osborne CK; Elledge RM
    J Natl Cancer Inst; 2005 Sep; 97(17):1254-61. PubMed ID: 16145046
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The impact of molecular subtype on breast cancer recurrence in young women treated with contemporary adjuvant therapy.
    Alabdulkareem H; Pinchinat T; Khan S; Landers A; Christos P; Simmons R; Moo TA
    Breast J; 2018 Mar; 24(2):148-153. PubMed ID: 28707744
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Meta-analysis of the association of breast cancer subtype and pathologic complete response to neoadjuvant chemotherapy.
    Houssami N; Macaskill P; von Minckwitz G; Marinovich ML; Mamounas E
    Eur J Cancer; 2012 Dec; 48(18):3342-54. PubMed ID: 22766518
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Magnetic resonance imaging as a predictor of pathologic response in patients treated with neoadjuvant systemic treatment for operable breast cancer. Translational Breast Cancer Research Consortium trial 017.
    De Los Santos JF; Cantor A; Amos KD; Forero A; Golshan M; Horton JK; Hudis CA; Hylton NM; McGuire K; Meric-Bernstam F; Meszoely IM; Nanda R; Hwang ES
    Cancer; 2013 May; 119(10):1776-83. PubMed ID: 23436342
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prognostic value of receptor conversion after neoadjuvant chemotherapy in breast cancer patients: a prospective observational study.
    Jin X; Jiang YZ; Chen S; Yu KD; Shao ZM; Di GH
    Oncotarget; 2015 Apr; 6(11):9600-11. PubMed ID: 25826079
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Breast cancer-specific survival by clinical subtype after 7 years follow-up of young and elderly women in a nationwide cohort.
    Johansson ALV; Trewin CB; Hjerkind KV; Ellingjord-Dale M; Johannesen TB; Ursin G
    Int J Cancer; 2019 Mar; 144(6):1251-1261. PubMed ID: 30367449
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Population-Based Study on Cancer Subtypes, Guideline-Concordant Adjuvant Therapy, and Survival Among Women With Stage I-III Breast Cancer.
    Hsieh MC; Zhang L; Wu XC; Davidson MB; Loch M; Chen VW
    J Natl Compr Canc Netw; 2019 Jun; 17(6):676-686. PubMed ID: 31200362
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Clinicopathological features and prognosis of hormone receptor-positive/human epidermal growth factor receptor 2-negative breast cancer].
    Wang Y; Zhang S; Zhang H; Liang L; Xu L; Cheng YJ; Duan XN; Liu YH; Li T
    Beijing Da Xue Xue Bao Yi Xue Ban; 2022 Oct; 54(5):853-862. PubMed ID: 36241228
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Real-world data on breast pathologic complete response and disease-free survival after neoadjuvant chemotherapy for hormone receptor-positive, human epidermal growth factor receptor-2-negative breast cancer: a multicenter, retrospective study in China.
    Guan D; Jie Q; Wu Y; Xu Y; Hong W; Meng X
    World J Surg Oncol; 2022 Sep; 20(1):326. PubMed ID: 36175898
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Age related influence of triple receptor status on metastatic breast cancer post relapse survival.
    Todorovic-Rakovic N; Neskovic-Konstantinovic Z
    J BUON; 2013; 18(4):851-8. PubMed ID: 24344008
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 28.